Bristol Myers Squibb (BMY) EBITDA (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of EBITDA data on file, last reported at $2.8 billion in Q1 2026.

• EBITDA for Q1 2026 came in at $2.8 billion, up 24.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 billion (up 35.84% YoY), and the FY2025 annual result was $6.8 billion, up 178.32% from the prior year.
• EBITDA climbed to $2.8 billion in Q1 2026 per BMY's latest filing, from $1.1 billion in the prior quarter.
• Over five years, EBITDA peaked at $2.8 billion in Q1 2026 and troughed at -$11.8 billion in Q1 2024.
• A 5-year average of $884.4 million and a median of $1.6 billion in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA plunged 640.92% in 2024, then surged 255.96% in 2025.
• A 5-year view of EBITDA shows it stood at $1.6 billion in 2022, then dropped by 5.06% to $1.5 billion in 2023, then slumped by 79.89% to $302.0 million in 2024, then surged by 255.96% to $1.1 billion in 2025, then surged by 163.44% to $2.8 billion in 2026.
• Business Quant data shows BMY's EBITDA at $2.8 billion in Q1 2026, $1.1 billion in Q4 2025, and $2.2 billion in Q3 2025.